Clinical Trials Logo

Fallopian Tube Cancer Stage IV clinical trials

View clinical trials related to Fallopian Tube Cancer Stage IV.

Filter by:
  • None
  • Page 1

NCT ID: NCT06290193 Recruiting - Ovarian Cancer Clinical Trials

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery

Start date: February 23, 2024
Phase: Phase 2
Study type: Interventional

Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution/ANH during surgery or standard surgical management during surgery. The researchers think acute normovolemic hemodilution/ANH may decrease the need for allogenic blood transfusion/ABT in people having primary cytoreductive surgery.

NCT ID: NCT04701645 Recruiting - Ovarian Cancer Clinical Trials

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This pilot study will assess the feasibility of using an implantable microdevice to measure local intratumor response to chemotherapy and other clinically relevant drugs in ovarian, fallopian tube, and primary peritoneal cancer. The name of the study intervention involved in this study is: -implantable microdevice

NCT ID: NCT03922776 Recruiting - Clinical trials for Ovarian Cancer Stage IV

Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer

TILsOV-1805
Start date: May 16, 2019
Phase: N/A
Study type: Interventional

This is a monocenter, interventional, non-randomized study among women patients with an ovarian or tubal cancer who will receive a surgery or adjuvant chemotherapy treatment, or a neo-adjuvant chemotherapy then surgery +/- adjuvant chemotherapy. The planned interventions are collection of biological samples at different times. The study will aim to describe the immunological profile at diagnosis in terms of phenotypic : PBMCs (peripheral blood, mononuclear cells) in peripheral blood, TILs (tumor-infiltrating lymphocytes) in ascites and in carcinomatosis.